Mitchell E. Gross, MD, PhD

Associate Professor of Clinical Medicine

Image of Mitchell E. Gross, MD, PhD
Is this your profile? Click to edit

Overview

Dr. Gross is research director of the USC Norris Westside Cancer Center and the Center for Applied Molecular Medicine. His overall research interest focuses on applying modern techniques relating to the study of genes and proteins (genomics and proteomics) on the clinical problems faced in treating patients with prostate cancer. A particular interest relates to the androgen receptor and relating proteins and pathways as key driving forces behind the development and treatment of prostate cancer. As a medical oncologist, his clinical activities are focused on therapeutic clinical trials incorporating both molecularly targeted and conventional therapies to the care of patients with prostate cancer. He serves as primary investigator on many multi-center phase 1 and 2 clinical trials

Dr. Gross has earned degrees from the University of California, San Diego (B.A.), Baylor College of Medicine in Houston (M.D.), and the University of California, Los Angeles (Ph.D. Molecular Biology). He completed a residency in internal medicine and a fellowship in hematology and medical oncology at the UCLA Center for the Health Sciences.

Awards

  • Phi Beta Kappa, 1989
  • UCSD/Revelle College Academic: Leadership Award, 1990
  • Alpha Omega Alpha, 1994
  • Hewlett Packard Award for Excellence in Internal Medicine, 1994
  • Specialty Training Advanced Research Fellowship, 1997
     – 2002
  • Amgen Fellowship Research Award, 1999
  • Rhone Phoulenc Rorer Travel Award, 1999
  • AACR-AFLAC Scholar in Training Award,, 2001
  • Donna and Jesse Garber Award, 2006

Research Funding

  • Selective Cancer Treatment Based on High Frequency Ultrasonic Beam
    NIH · R21EB022932 · Sep 16, 2016 – Jul 31, 2018 · Role: Co-Principal Investigator
  • Role of PIASy in Androgen Signaling and Prostate Cancer
    NIH · K08DK064379 · Aug 21, 2002 – Jun 30, 2007 · Role: Principal Investigator

Publications

  • Cytometric comparisons between circulating tumor cells from prostate cancer patients and the prostate-tumor-derived LNCaP cell line. Phys Biol. 2012 Feb; 9(1):016002.. View in PubMed
  • 3-Dimensional elastic registration system of prostate biopsy location by real-time 3-dimensional transrectal ultrasound guidance with magnetic resonance/transrectal ultrasound image fusion. J Urol. 2012 Mar; 187(3):1080-6.. View in PubMed
  • Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. Cancer Chemother Pharmacol. 2012 Jan; 69(1):273-80.. View in PubMed
  • The epothilones: new therapeutic agents for castration-resistant prostate cancer. Oncologist. 2011; 16(10):1349-58.. View in PubMed
  • Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology. 2011 May; 77(5):1166-71.. View in PubMed
  • Show us a sign: the search for “game changing” prostate cancer biomarkers. Lancet Oncol. 2011 Mar; 12(3):204-6.. View in PubMed
  • Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling. Prostate. 2010 Aug; 70(11):1201-10.. View in PubMed
  • Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem. 2010 Sep; 56(9):1492-5.. View in PubMed
  • Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest New Drugs. 2011 Dec; 29(6):1432-40.. View in PubMed
  • Predictors of affect following treatment decision-making for prostate cancer: conversations, cognitive processing, and coping. Psychooncology. 2009 May; 18(5):508-14.. View in PubMed